Leading RNA drug developer Suzhou Ribo Life Science Co. Ltd. passed its hearing for a listing on the Hong Kong Stock Exchange, marking the official launch of its IPO, according to its post-hearing ...

The transition from simple chemistry to the complex biology of molecules that gave rise to life is a puzzle that scientists ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

HELIOS-B is a global, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of AMVUTTRA (R) in adult patients with wtATTR or hATTR amyloidosis with ...

In this interview, Dr. Gary Pestano and Dr. Prithwish Pal discuss the advantages ddPCR offers in molecular residual disease ...

The Others in Pluribus are so tranquil and peace-loving that they somehow come across as strangely sinister, which makes me think they aren't quite the wholesom ...

TV in 2025 is a churning mass of streamers, sub-streamers, niche service tiers and algorithmic “content verticals” ...

These sequences are extremely prone to mutations and rank among the most functionally important regions in the entire human ...

Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada ...

The authors provide a useful integrated analytical approach to investigating MASLD focused on diverse multiomic integration methods. The strength of evidence for this new resource is solid, as ...

Throughout history, many viral diseases have proven difficult to treat. However, recent research into synthetic drugs has given medical science powerful new tools to combat these pathogens. One ...

Thymagen (also called thymogen; dipeptide Glu-Trp, EW) is a synthetic peptide analog derived from thymic extracts and regarded in peptide bioregulator research for its putative immunoregulatory and ...